Evolving models of care in patients with metabolic dysfunction-associated steatotic liver disease, recognising its population burden and the impact of metabolic dysfunction on incident rates of hepatic and extrahepatic outcomes
Metabolism and Target Organ Damage · 29.05.2025 · 5 (2)
DOI: 10.20517/mtod.2025.28 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolism and Target Organ Damage, online erschienen am 29.05.2025. Verfasst von Josh Bilson und 2 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with any one of five principal traits of the metabolic syndrome. MASLD is characterised by multimorbidity with liver-related and extrahepatic complications including cardiovascular and cardiac disease, chronic kidney disease and certain extrahepatic cancers. While increasing liver fibrosis severity is well-established as a major contributor to the hepatic complications of MASLD, emerging evidence demonstrates that the severity of associated metabolic dysfunction significantly influences adverse extrahepatic clinical outcomes and all-cause mortality. Changing models of care are needed for patients with MASLD, extending the focus beyond that of liver health and optimising the inherent (heterogeneous) cardiometabolic dysfunction. Such an approach requires multi-stakeholder and community-based engagement with improved identification and diagnosis, and better patient and healthcare provider education that also focuses on type 2 diabetes, hypertension, and obesity, to ameliorate the consequences of this highly prevalent global multisystem disease.
Zitieren
APA
Bilson, J., Cuthbertson, D. J., & Byrne, C. D. (2025). Evolving models of care in patients with metabolic dysfunction-associated steatotic liver disease, recognising its population burden and the impact of metabolic dysfunction on incident rates of hepatic and extrahepatic outcomes. Metabolism and Target Organ Damage, 5(2). https://doi.org/10.20517/mtod.2025.28
Vancouver
Bilson J, Cuthbertson DJ, Byrne CD. Evolving models of care in patients with metabolic dysfunction-associated steatotic liver disease, recognising its population burden and the impact of metabolic dysfunction on incident rates of hepatic and extrahepatic outcomes. Metabolism and Target Organ Damage. 2025;5(2). doi:10.20517/mtod.2025.28
BibTeX
@article{Bilson2025,
author = {Bilson, Josh and Cuthbertson, Daniel J. and Byrne, Christopher D.},
title = {Evolving models of care in patients with metabolic dysfunction-associated steatotic liver disease, recognising its population burden and the impact of metabolic dysfunction on incident rates of hepatic and extrahepatic outcomes},
journal = {Metabolism and Target Organ Damage},
year = {2025},
volume = {5},
number = {2},
doi = {10.20517/mtod.2025.28}
}
EUVIMED